Global big pharmaceutical companies have overcome the stagnant growth amid the COVID-19 pandemic.
As Newsmp tallied the semi-annual reports of major global big pharmaceuticals, it was found that most of the big pharma recorded double-digit growth.
The company with the biggest growth was Pfizer, whose quarterly sales surged 92.4% from 11.27 trillion to 21.07 trillion won due to the COVID-19 vaccine (based on the exchange rate as of August 5).
Following Pfizer, AbbVie grew 33.9% and AstraZeneca 31.0%, while Johnson & Johnson, Eli Lilly, MSD, and Gilead Sciences exceeded more than 20% growth.
In particular, the vaccine manufacturer Pfizer, AstraZeneca, and Johnson & Johnson (Janssen) recorded considerable growth, over 20%.
GSK’s growth was close to 20%, and quarterly sales of BMS, Novartis, Roche, and Novo Nordisk also increased by more than 10%.
Sanofi and Amgen, which fell 4% in the first quarter, showed only single-digit growth but freed from the negative growth trend.
With the recovery in 2Q earnings, all of the semi-annual sales turned to growth. Pfizer’s 1H sales surged 68.2% YoY.
AbbVie’s sales also soared more than 40% due to the merger with Allergan, and AstraZeneca’s growth also exceeded 20%.
Meanwhile, Eli Lilly, Gilead Sciences, and MSD recorded double-digit growth.